D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock.

A number of other brokerages have also weighed in on IVVD. HC Wainwright decreased their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Morgan Stanley decreased their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $7.89.

Invivyd Trading Down 2.1 %

IVVD stock opened at $0.45 on Friday. The stock has a market capitalization of $54.07 million, a PE ratio of -0.23 and a beta of 0.64. Invivyd has a 12-month low of $0.40 and a 12-month high of $5.20. The stock’s 50 day simple moving average is $0.64 and its 200 day simple moving average is $0.91.

Insider Buying and Selling at Invivyd

In other news, Director Terrance Mcguire sold 150,000 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $0.61, for a total value of $91,500.00. Following the completion of the sale, the director now directly owns 4,538,079 shares in the company, valued at $2,768,228.19. This represents a 3.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last ninety days, insiders sold 816,466 shares of company stock worth $423,214. Insiders own 17.90% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Several hedge funds and other institutional investors have recently modified their holdings of IVVD. Bank of New York Mellon Corp purchased a new stake in Invivyd in the 2nd quarter worth $263,000. Rhumbline Advisers increased its stake in Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after buying an additional 82,164 shares in the last quarter. Acadian Asset Management LLC increased its stake in Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after buying an additional 474,301 shares in the last quarter. Cornercap Investment Counsel Inc. purchased a new stake in Invivyd in the 2nd quarter worth $86,000. Finally, Renaissance Technologies LLC purchased a new stake in Invivyd in the 2nd quarter worth $421,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.